Bad Blood

This is not a business legend written from imagination, but an account delivered by an investigative reporter after years of dealing with whistleblowers, lawyers, and private investigators. Carreyrou spent more than twenty years on investigative reporting at The Wall Street Journal and won the Pulitzer Prize twice; his series of reports on Theranos directly prompted regulatory intervention and the company's collapse, and this book is the complete version of that reporting. Its appeal lies in two lines advancing at once: one is how the myth was built layer by layer -- dropping out of an elite school, a vision to change the world, endorsements from a star-studded board, media adulation, ever-rising valuations; the other is how the truth was dug out bit by bit -- employees' doubts, suppressed data, intimidated witnesses, modified instruments. The two lines intersect, letting readers see both the technical details of the fraud and how reputation, capital, and fear made people collectively silent. The 2025 edition adds the author's afterword covering new developments in the trial, extending the book from exposure to accountability. For readers concerned with the startup ecosystem, investment judgment, and business ethics, it offers not just a curious story but a method for recognizing narrative that outstrips product.